Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis: Impact of Timing of Treatment Initiation-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis: Impact of Timing of Treatment Initiation

Published:2019-07 Issue:7 Volume:16 Page:927-930
ISSN:2329-6933
Container-title:Annals of the American Thoracic Society
language:en
Short-container-title:Annals ATS

Author:

Maher Toby M.¹²,Lancaster Lisa H.³,Jouneau Stéphane⁴⁵,Morrison Lake⁶,Lederer David J.⁷^ORCID,Molina-Molina Maria⁸⁹,Bendstrup Elisabeth¹⁰,Kirchgaessler Klaus-Uwe¹¹,Gilberg Frank¹¹,Axmann Judit¹¹,Petzinger Ute¹²,Noble Paul W.¹³

Affiliation:

1. Royal Brompton HospitalLondon, United Kingdom

2. Imperial College LondonLondon, United Kingdom

3. Vanderbilt University Medical CenterNashville, Tennessee

4. Pontchaillou University HospitalRennes, France

5. Rennes 1 UniversityRennes, France

6. Duke University Medical CenterDurham, North Carolina

7. Columbia University Medical CenterNew York, New York

8. Institut d’Investigació Biomèdica de BellvitgeBarcelona, Spain

9. Centro de Investigación Biomédica en Red Enfermedades RespiratoriasMadrid, Spain

10. Aarhus University HospitalAarhus, Denmark

11. F. Hoffmann-La Roche, Ltd.Basel, Switzerland

12. Accovion GmbHEschborn, Germanyand

13. Cedars-Sinai Medical CenterLos Angeles, California

Publisher

American Thoracic Society

Subject

Pulmonary and Respiratory Medicine

Link

https://www.atsjournals.org/doi/pdf/10.1513/AnnalsATS.201810-720RL

Reference12 articles.

1. Clinical Course and Prediction of Survival in Idiopathic Pulmonary Fibrosis

2. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline

3. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials

4. A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

5. Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Relationship between idiopathic interstitial pneumonias (IIPs) and connective tissue disease-related interstitial lung disease (CTD-ILD): A narrative review;Respiratory Investigation;2024-05

2. Bibliometric analysis of the pirfenidone and nintedanib in interstitial lung diseases;Heliyon;2024-04

3. Mast-cell expressed membrane protein-1 is expressed in classical monocytes and alveolar macrophages in idiopathic pulmonary fibrosis and regulates cell chemotaxis, adhesion, and migration in a TGFβ-dependent manner;American Journal of Physiology-Cell Physiology;2024-03-01

4. A Comparison of the Effectiveness of Nintedanib and Pirfenidone in Treating Idiopathic Pulmonary Fibrosis: A Systematic Review;Cureus;2024-02-15

5. Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: A position statement from the Thoracic Society of Australia and New Zealand 2023 revision;Respirology;2024-01-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3